Jackson Creek Investment Advisors LLC Acquires New Holdings in CareDx, Inc. $CDNA

Jackson Creek Investment Advisors LLC acquired a new stake in CareDx, Inc. (NASDAQ:CDNA) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 26,990 shares of the company’s stock, valued at approximately $508,000. Jackson Creek Investment Advisors LLC owned about 0.05% of CareDx at the end of the most recent quarter.

A number of other large investors have also recently added to or reduced their stakes in CDNA. Goldman Sachs Group Inc. grew its stake in CareDx by 18.1% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,110,014 shares of the company’s stock valued at $19,703,000 after acquiring an additional 170,504 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in shares of CareDx by 11.3% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 133,966 shares of the company’s stock worth $2,378,000 after purchasing an additional 13,619 shares during the last quarter. JPMorgan Chase & Co. boosted its stake in shares of CareDx by 41.2% during the 2nd quarter. JPMorgan Chase & Co. now owns 68,602 shares of the company’s stock worth $1,340,000 after purchasing an additional 20,028 shares during the last quarter. First Trust Advisors LP acquired a new stake in shares of CareDx during the 2nd quarter worth about $1,822,000. Finally, Nebula Research & Development LLC acquired a new stake in shares of CareDx during the 2nd quarter worth about $281,000.

Insider Activity

In related news, CEO John Walter Hanna, Jr. sold 10,282 shares of the firm’s stock in a transaction that occurred on Thursday, April 16th. The shares were sold at an average price of $21.12, for a total value of $217,155.84. Following the sale, the chief executive officer directly owned 676,475 shares of the company’s stock, valued at approximately $14,287,152. This trade represents a 1.50% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 4.40% of the company’s stock.

CareDx Stock Performance

CDNA opened at $22.16 on Thursday. The company’s 50 day simple moving average is $19.54 and its 200 day simple moving average is $19.07. CareDx, Inc. has a 1 year low of $10.96 and a 1 year high of $23.24. The stock has a market capitalization of $1.14 billion, a PE ratio of -138.50 and a beta of 2.49.

CareDx (NASDAQ:CDNA) last released its earnings results on Tuesday, April 28th. The company reported $0.34 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.11 by $0.23. CareDx had a negative net margin of 2.01% and a negative return on equity of 2.65%. The business had revenue of $117.70 million for the quarter, compared to analysts’ expectations of $102.03 million. During the same period last year, the company earned $0.09 earnings per share. The company’s quarterly revenue was up 39.3% on a year-over-year basis. As a group, sell-side analysts expect that CareDx, Inc. will post 0.22 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have issued reports on the stock. BTIG Research raised their price target on shares of CareDx from $26.00 to $28.00 and gave the stock a “buy” rating in a research note on Wednesday, April 29th. Wall Street Zen raised shares of CareDx from a “buy” rating to a “strong-buy” rating in a research note on Sunday, May 3rd. Weiss Ratings cut shares of CareDx from a “hold (c-)” rating to a “sell (d)” rating in a research note on Friday, February 27th. Finally, Wells Fargo & Company raised their price target on shares of CareDx from $18.00 to $21.00 and gave the stock an “equal weight” rating in a research note on Wednesday, February 25th. One equities research analyst has rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, CareDx has a consensus rating of “Hold” and a consensus target price of $25.00.

CareDx Company Profile

CareDx, Inc (NASDAQ: CDNA) is a precision diagnostics company focused on the care of transplant patients. The firm develops and commercializes non?invasive tests designed to detect organ transplant rejection and infection risk, helping physicians make informed management decisions throughout the post?transplant journey.

The company’s core product portfolio includes AlloMap®, a gene expression profiling test for heart transplant recipients, and AlloSure®, a donor?derived cell?free DNA assay used primarily in kidney transplant monitoring.